Sign In
Buy BHVN
$13.50
-0.320 (-2.32%)
At Close: Jul 31, 2026
Biohaven: Downgrade To Hold On Troriluzole Setback And Obesity Data 2nd Half 2026
04:07pm, Wednesday, 15'th Apr 2026
Biohaven Ltd. is downgraded from Strong Buy to Hold following the FDA's Complete Response Letter for troriluzole in Spinocerebellar Ataxia. BHVN pivots focus to three late-stage programs: MODE/TRAP de
Why Biohaven Stock Crushed it on Monday
05:41pm, Monday, 13'th Apr 2026
That pundit flagged the stock as a buy. He also expects it to more than double in price.
Aberdeen Group plc Buys Shares of 693,452 Biohaven Ltd. $BHVN
03:37am, Thursday, 09'th Apr 2026
Aberdeen Group plc bought a new stake in Biohaven Ltd. (NYSE: BHVN) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The f
SG Americas Securities LLC Grows Holdings in Biohaven Ltd. $BHVN
04:47am, Wednesday, 08'th Apr 2026
SG Americas Securities LLC grew its holdings in shares of Biohaven Ltd. (NYSE: BHVN) by 291.8% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential
01:17pm, Monday, 23'rd Mar 2026
Sarissa Capital Management added 513,184 shares in Biohaven during the fourth quarter. The quarter-end position value increased by $5.79 million as a result of the transaction.
Biohaven Ltd. (NYSE:BHVN) Given Average Recommendation of “Moderate Buy” by Brokerages
02:31am, Sunday, 22'nd Mar 2026
Biohaven Ltd. (NYSE: BHVN - Get Free Report) has earned an average recommendation of "Moderate Buy" from the seventeen brokerages that are covering the stock, MarketBeat.com reports. One equities rese
This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash
07:49pm, Saturday, 21'st Mar 2026
DAFNA Capital Management bought 720,000 shares of Biohaven in the fourth quarter; the estimated trade size was $8.92 million, based on average prices in the fourth quarter of 2025. Meanwhile, the quar
Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment
07:30am, Thursday, 19'th Mar 2026
Phase 2 study in obesity, evaluating treatment with once-weekly and once-monthly taldefgrobep alfa as monotherapy, is now fully enrolled; topline data expected in 2H 2026. Taldefgrobep is a novel inhi
What's Going On With Biohaven Stock On Monday?
11:47am, Monday, 09'th Mar 2026
Biohaven shares rose in premarket trading after Xenon's Phase 3 epilepsy study showed strong seizure reduction results.
Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results
04:05pm, Monday, 02'nd Mar 2026
Prioritizing three key, late-stage clinical programs including Molecular Degrader of Extracellular Proteins (MoDETM) and Targeted Removal of Aberrant Protein (TRAPTM) extracellular protein degradatio
Is Biohaven Ltd. (BHVN) Stock Outpacing Its Medical Peers This Year?
10:40am, Tuesday, 10'th Feb 2026
Here is how Biohaven Ltd. (BHVN) and Caribou Biosciences, Inc. (CRBU) have performed compared to their sector so far this year.
Does Biohaven Ltd. (BHVN) Have the Potential to Rally 82.16% as Wall Street Analysts Expect?
10:56am, Monday, 09'th Feb 2026
The consensus price target hints at an 82.2% upside potential for Biohaven Ltd. (BHVN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings es
Goldman Sachs Just Upgraded These 3 Stocks to a Buy Rating
09:26am, Monday, 09'th Feb 2026
Goldman initiated a buy rating on Biohaven targeting its IgAN treatment in an over $40B U.S. market.
Pre-Market Stock Futures: Futures are trading higher as we prepare to wrap up one of the worst trading weeks in some time. The song remains the same as the rotation out of the tech trade continues to
Biohaven (BHVN) Stock Is Trending Overnight — Here's What You Should Know
09:48pm, Wednesday, 14'th Jan 2026
Biohaven Ltd. shares surged 3.42% in after-hours trading following an SEC filing that detailed investor presentations and updates on its drug pipeline.
